1 Spinal Muscular Atrophy Medicine Market Overview 1.1 Product Overview and Scope of Spinal Muscular Atrophy Medicine 1.2 Spinal Muscular Atrophy Medicine Segment by Type 1.2.1 Global Spinal Muscular Atrophy Medicine Market Value Comparison by Type (2023-2029) 1.2.2 LMI-070 1.2.3 ND-602 1.2.4 NT-1654 1.2.5 Nusinersen 1.2.6 NXD-30001 1.2.7 Others 1.3 Spinal Muscular Atrophy Medicine Segment by Application 1.3.1 Global Spinal Muscular Atrophy Medicine Market Value by Application: (2023-2029) 1.3.2 Hospital 1.3.3 Clinic 1.3.4 Others 1.4 Global Spinal Muscular Atrophy Medicine Market Size Estimates and Forecasts 1.4.1 Global Spinal Muscular Atrophy Medicine Revenue 2018-2029 1.4.2 Global Spinal Muscular Atrophy Medicine Sales 2018-2029 1.4.3 Global Spinal Muscular Atrophy Medicine Market Average Price (2018-2029) 1.5 Assumptions and Limitations 2 Spinal Muscular Atrophy Medicine Market Competition by Manufacturers 2.1 Global Spinal Muscular Atrophy Medicine Sales Market Share by Manufacturers (2018-2023) 2.2 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Manufacturers (2018-2023) 2.3 Global Spinal Muscular Atrophy Medicine Average Price by Manufacturers (2018-2023) 2.4 Global Spinal Muscular Atrophy Medicine Industry Ranking 2021 VS 2022 VS 2023 2.5 Global Key Manufacturers of Spinal Muscular Atrophy Medicine, Manufacturing Sites & Headquarters 2.6 Global Key Manufacturers of Spinal Muscular Atrophy Medicine, Product Type & Application 2.7 Spinal Muscular Atrophy Medicine Market Competitive Situation and Trends 2.7.1 Spinal Muscular Atrophy Medicine Market Concentration Rate 2.7.2 The Global Top 5 and Top 10 Largest Spinal Muscular Atrophy Medicine Players Market Share by Revenue 2.7.3 Global Spinal Muscular Atrophy Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.8 Manufacturers Mergers & Acquisitions, Expansion Plans 3 Spinal Muscular Atrophy Medicine Retrospective Market Scenario by Region 3.1 Global Spinal Muscular Atrophy Medicine Market Size by Region: 2018 Versus 2022 Versus 2029 3.2 Global Spinal Muscular Atrophy Medicine Global Spinal Muscular Atrophy Medicine Sales by Region: 2018-2029 3.2.1 Global Spinal Muscular Atrophy Medicine Sales by Region: 2018-2023 3.2.2 Global Spinal Muscular Atrophy Medicine Sales by Region: 2024-2029 3.3 Global Spinal Muscular Atrophy Medicine Global Spinal Muscular Atrophy Medicine Revenue by Region: 2018-2029 3.3.1 Global Spinal Muscular Atrophy Medicine Revenue by Region: 2018-2023 3.3.2 Global Spinal Muscular Atrophy Medicine Revenue by Region: 2024-2029 3.4 North America Spinal Muscular Atrophy Medicine Market Facts & Figures by Country 3.4.1 North America Spinal Muscular Atrophy Medicine Market Size by Country: 2018 VS 2022 VS 2029 3.4.2 North America Spinal Muscular Atrophy Medicine Sales by Country (2018-2029) 3.4.3 North America Spinal Muscular Atrophy Medicine Revenue by Country (2018-2029) 3.4.4 U.S. 3.4.5 Canada 3.5 Europe Spinal Muscular Atrophy Medicine Market Facts & Figures by Country 3.5.1 Europe Spinal Muscular Atrophy Medicine Market Size by Country: 2018 VS 2022 VS 2029 3.5.2 Europe Spinal Muscular Atrophy Medicine Sales by Country (2018-2029) 3.5.3 Europe Spinal Muscular Atrophy Medicine Revenue by Country (2018-2029) 3.5.4 Germany 3.5.5 France 3.5.6 U.K. 3.5.7 Italy 3.5.8 Russia 3.6 Asia Pacific Spinal Muscular Atrophy Medicine Market Facts & Figures by Country 3.6.1 Asia Pacific Spinal Muscular Atrophy Medicine Market Size by Country: 2018 VS 2022 VS 2029 3.6.2 Asia Pacific Spinal Muscular Atrophy Medicine Sales by Country (2018-2029) 3.6.3 Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Country (2018-2029) 3.6.4 China 3.6.5 Japan 3.6.6 South Korea 3.6.7 India 3.6.8 Australia 3.6.9 Taiwan 3.6.10 Indonesia 3.6.11 Thailand 3.6.12 Malaysia 3.6.13 Philippines 3.7 Latin America Spinal Muscular Atrophy Medicine Market Facts & Figures by Country 3.7.1 Latin America Spinal Muscular Atrophy Medicine Market Size by Country: 2018 VS 2022 VS 2029 3.7.2 Latin America Spinal Muscular Atrophy Medicine Sales by Country (2018-2029) 3.7.3 Latin America Spinal Muscular Atrophy Medicine Revenue by Country (2018-2029) 3.7.4 Mexico 3.7.5 Brazil 3.7.6 Argentina 3.8 Middle East and Africa Spinal Muscular Atrophy Medicine Market Facts & Figures by Country 3.8.1 Middle East and Africa Spinal Muscular Atrophy Medicine Market Size by Country: 2018 VS 2022 VS 2029 3.8.2 Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country (2018-2029) 3.8.3 Middle East and Africa Spinal Muscular Atrophy Medicine Revenue by Country (2018-2029) 3.8.4 Turkey 3.8.5 Saudi Arabia 3.8.6 U.A.E 4 Segment by Type 4.1 Global Spinal Muscular Atrophy Medicine Sales by Type (2018-2029) 4.1.1 Global Spinal Muscular Atrophy Medicine Sales by Type (2018-2023) 4.1.2 Global Spinal Muscular Atrophy Medicine Sales by Type (2024-2029) 4.1.3 Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2018-2029) 4.2 Global Spinal Muscular Atrophy Medicine Revenue by Type (2018-2029) 4.2.1 Global Spinal Muscular Atrophy Medicine Revenue by Type (2018-2023) 4.2.2 Global Spinal Muscular Atrophy Medicine Revenue by Type (2024-2029) 4.2.3 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2018-2029) 4.3 Global Spinal Muscular Atrophy Medicine Price by Type (2018-2029) 5 Segment by Application 5.1 Global Spinal Muscular Atrophy Medicine Sales by Application (2018-2029) 5.1.1 Global Spinal Muscular Atrophy Medicine Sales by Application (2018-2023) 5.1.2 Global Spinal Muscular Atrophy Medicine Sales by Application (2024-2029) 5.1.3 Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2018-2029) 5.2 Global Spinal Muscular Atrophy Medicine Revenue by Application (2018-2029) 5.2.1 Global Spinal Muscular Atrophy Medicine Revenue by Application (2018-2023) 5.2.2 Global Spinal Muscular Atrophy Medicine Revenue by Application (2024-2029) 5.2.3 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2018-2029) 5.3 Global Spinal Muscular Atrophy Medicine Price by Application (2018-2029) 6 Key Companies Profiled 6.1 Astellas Pharma Inc. 6.1.1 Astellas Pharma Inc. Corporation Information 6.1.2 Astellas Pharma Inc. Description and Business Overview 6.1.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023) 6.1.4 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Portfolio 6.1.5 Astellas Pharma Inc. Recent Developments/Updates 6.2 AveXis, Inc. 6.2.1 AveXis, Inc. Corporation Information 6.2.2 AveXis, Inc. Description and Business Overview 6.2.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023) 6.2.4 AveXis, Inc. Spinal Muscular Atrophy Medicine Product Portfolio 6.2.5 AveXis, Inc. Recent Developments/Updates 6.3 Bioblast Pharma Ltd. 6.3.1 Bioblast Pharma Ltd. Corporation Information 6.3.2 Bioblast Pharma Ltd. Description and Business Overview 6.3.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023) 6.3.4 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Portfolio 6.3.5 Bioblast Pharma Ltd. Recent Developments/Updates 6.4 Cytokinetics, Inc. 24 6.4.1 Cytokinetics, Inc. 24 Corporation Information 6.4.2 Cytokinetics, Inc. 24 Description and Business Overview 6.4.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023) 6.4.4 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Portfolio 6.4.5 Cytokinetics, Inc. 24 Recent Developments/Updates 6.5 F. Hoffmann-La Roche Ltd. 6.5.1 F. Hoffmann-La Roche Ltd. Corporation Information 6.5.2 F. Hoffmann-La Roche Ltd. Description and Business Overview 6.5.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023) 6.5.4 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Portfolio 6.5.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates 6.6 Genethon 6.6.1 Genethon Corporation Information 6.6.2 Genethon Description and Business Overview 6.6.3 Genethon Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023) 6.6.4 Genethon Spinal Muscular Atrophy Medicine Product Portfolio 6.6.5 Genethon Recent Developments/Updates 6.7 Genzyme Corporation 6.6.1 Genzyme Corporation Corporation Information 6.6.2 Genzyme Corporation Description and Business Overview 6.6.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023) 6.4.4 Genzyme Corporation Spinal Muscular Atrophy Medicine Product Portfolio 6.7.5 Genzyme Corporation Recent Developments/Updates 6.8 GMP-Orphan SAS 6.8.1 GMP-Orphan SAS Corporation Information 6.8.2 GMP-Orphan SAS Description and Business Overview 6.8.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023) 6.8.4 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Portfolio 6.8.5 GMP-Orphan SAS Recent Developments/Updates 6.9 Ionis Pharmaceuticals, Inc. 6.9.1 Ionis Pharmaceuticals, Inc. Corporation Information 6.9.2 Ionis Pharmaceuticals, Inc. Description and Business Overview 6.9.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023) 6.9.4 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Portfolio 6.9.5 Ionis Pharmaceuticals, Inc. Recent Developments/Updates 6.10 Longevity Biotech, Inc 6.10.1 Longevity Biotech, Inc Corporation Information 6.10.2 Longevity Biotech, Inc Description and Business Overview 6.10.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023) 6.10.4 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Portfolio 6.10.5 Longevity Biotech, Inc Recent Developments/Updates 6.11 Neurodyn Inc. 6.11.1 Neurodyn Inc. Corporation Information 6.11.2 Neurodyn Inc. Spinal Muscular Atrophy Medicine Description and Business Overview 6.11.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023) 6.11.4 Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Portfolio 6.11.5 Neurodyn Inc. Recent Developments/Updates 6.12 Neurotune AG 6.12.1 Neurotune AG Corporation Information 6.12.2 Neurotune AG Spinal Muscular Atrophy Medicine Description and Business Overview 6.12.3 Neurotune AG Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023) 6.12.4 Neurotune AG Spinal Muscular Atrophy Medicine Product Portfolio 6.12.5 Neurotune AG Recent Developments/Updates 6.13 Novartis AG 6.13.1 Novartis AG Corporation Information 6.13.2 Novartis AG Spinal Muscular Atrophy Medicine Description and Business Overview 6.13.3 Novartis AG Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023) 6.13.4 Novartis AG Spinal Muscular Atrophy Medicine Product Portfolio 6.13.5 Novartis AG Recent Developments/Updates 6.14 Sarepta Therapeutics, Inc. 6.14.1 Sarepta Therapeutics, Inc. Corporation Information 6.14.2 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Description and Business Overview 6.14.3 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023) 6.14.4 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolio 6.14.5 Sarepta Therapeutics, Inc. Recent Developments/Updates 6.15 Voyager Therapeutics, Inc. 6.15.1 Voyager Therapeutics, Inc. Corporation Information 6.15.2 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Description and Business Overview 6.15.3 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023) 6.15.4 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolio 6.15.5 Voyager Therapeutics, Inc. Recent Developments/Updates 6.16 Vybion, Inc. 6.16.1 Vybion, Inc. Corporation Information 6.16.2 Vybion, Inc. Spinal Muscular Atrophy Medicine Description and Business Overview 6.16.3 Vybion, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023) 6.16.4 Vybion, Inc. Spinal Muscular Atrophy Medicine Product Portfolio 6.16.5 Vybion, Inc. Recent Developments/Updates 6.17 WAVE Life Sciences Ltd. 6.17.1 WAVE Life Sciences Ltd. Corporation Information 6.17.2 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Description and Business Overview 6.17.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023) 6.17.4 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Portfolio 6.17.5 WAVE Life Sciences Ltd. Recent Developments/Updates 7 Industry Chain and Sales Channels Analysis 7.1 Spinal Muscular Atrophy Medicine Industry Chain Analysis 7.2 Spinal Muscular Atrophy Medicine Key Raw Materials 7.2.1 Key Raw Materials 7.2.2 Raw Materials Key Suppliers 7.3 Spinal Muscular Atrophy Medicine Production Mode & Process 7.4 Spinal Muscular Atrophy Medicine Sales and Marketing 7.4.1 Spinal Muscular Atrophy Medicine Sales Channels 7.4.2 Spinal Muscular Atrophy Medicine Distributors 7.5 Spinal Muscular Atrophy Medicine Customers 8 Spinal Muscular Atrophy Medicine Market Dynamics 8.1 Spinal Muscular Atrophy Medicine Industry Trends 8.2 Spinal Muscular Atrophy Medicine Market Drivers 8.3 Spinal Muscular Atrophy Medicine Market Challenges 8.4 Spinal Muscular Atrophy Medicine Market Restraints 9 Research Finding and Conclusion 10 Methodology and Data Source 10.1 Methodology/Research Approach 10.1.1 Research Programs/Design 10.1.2 Market Size Estimation 10.1.3 Market Breakdown and Data Triangulation 10.2 Data Source 10.2.1 Secondary Sources 10.2.2 Primary Sources 10.3 Author List 10.4 Disclaimer

List of Tables Table 1. Global Spinal Muscular Atrophy Medicine Market Value Comparison by Type (2023-2029) & (US$ Million) Table 2. Global Spinal Muscular Atrophy Medicine Market Value Comparison by Application (2023-2029) & (US$ Million) Table 3. Global Spinal Muscular Atrophy Medicine Market Competitive Situation by Manufacturers in 2022 Table 4. Global Spinal Muscular Atrophy Medicine Sales (K Pcs) of Key Manufacturers (2018-2023) Table 5. Global Spinal Muscular Atrophy Medicine Sales Market Share by Manufacturers (2018-2023) Table 6. Global Spinal Muscular Atrophy Medicine Revenue (US$ Million) by Manufacturers (2018-2023) Table 7. Global Spinal Muscular Atrophy Medicine Revenue Share by Manufacturers (2018-2023) Table 8. Global Market Spinal Muscular Atrophy Medicine Average Price (USD/Pcs) of Key Manufacturers (2018-2023) Table 9. Global Key Players of Spinal Muscular Atrophy Medicine, Industry Ranking, 2021 VS 2022 VS 2023 Table 10. Global Key Manufacturers of Spinal Muscular Atrophy Medicine, Manufacturing Sites & Headquarters Table 11. Global Key Manufacturers of Spinal Muscular Atrophy Medicine, Product Type & Application Table 12. Global Key Manufacturers of Spinal Muscular Atrophy Medicine, Date of Enter into This Industry Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 14. Global Spinal Muscular Atrophy Medicine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Spinal Muscular Atrophy Medicine as of 2022) Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans Table 16. Global Spinal Muscular Atrophy Medicine Market Size by Region (US$ Million): 2018 VS 2022 VS 2029 Table 17. Global Spinal Muscular Atrophy Medicine Sales by Region (2018-2023) & (K Pcs) Table 18. Global Spinal Muscular Atrophy Medicine Sales Market Share by Region (2018-2023) Table 19. Global Spinal Muscular Atrophy Medicine Sales by Region (2024-2029) & (K Pcs) Table 20. Global Spinal Muscular Atrophy Medicine Sales Market Share by Region (2024-2029) Table 21. Global Spinal Muscular Atrophy Medicine Revenue by Region (2018-2023) & (US$ Million) Table 22. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2018-2023) Table 23. Global Spinal Muscular Atrophy Medicine Revenue by Region (2024-2029) & (US$ Million) Table 24. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2024-2029) Table 25. North America Spinal Muscular Atrophy Medicine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million) Table 26. North America Spinal Muscular Atrophy Medicine Sales by Country (2018-2023) & (K Pcs) Table 27. North America Spinal Muscular Atrophy Medicine Sales by Country (2024-2029) & (K Pcs) Table 28. North America Spinal Muscular Atrophy Medicine Revenue by Country (2018-2023) & (US$ Million) Table 29. North America Spinal Muscular Atrophy Medicine Revenue by Country (2024-2029) & (US$ Million) Table 30. Europe Spinal Muscular Atrophy Medicine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million) Table 31. Europe Spinal Muscular Atrophy Medicine Sales by Country (2018-2023) & (K Pcs) Table 32. Europe Spinal Muscular Atrophy Medicine Sales by Country (2024-2029) & (K Pcs) Table 33. Europe Spinal Muscular Atrophy Medicine Revenue by Country (2018-2023) & (US$ Million) Table 34. Europe Spinal Muscular Atrophy Medicine Revenue by Country (2024-2029) & (US$ Million) Table 35. Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million) Table 36. Asia Pacific Spinal Muscular Atrophy Medicine Sales by Region (2018-2023) & (K Pcs) Table 37. Asia Pacific Spinal Muscular Atrophy Medicine Sales by Region (2024-2029) & (K Pcs) Table 38. Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Region (2018-2023) & (US$ Million) Table 39. Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Region (2024-2029) & (US$ Million) Table 40. Latin America Spinal Muscular Atrophy Medicine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million) Table 41. Latin America Spinal Muscular Atrophy Medicine Sales by Country (2018-2023) & (K Pcs) Table 42. Latin America Spinal Muscular Atrophy Medicine Sales by Country (2024-2029) & (K Pcs) Table 43. Latin America Spinal Muscular Atrophy Medicine Revenue by Country (2018-2023) & (US$ Million) Table 44. Latin America Spinal Muscular Atrophy Medicine Revenue by Country (2024-2029) & (US$ Million) Table 45. Middle East & Africa Spinal Muscular Atrophy Medicine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million) Table 46. Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Country (2018-2023) & (K Pcs) Table 47. Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Country (2024-2029) & (K Pcs) Table 48. Middle East & Africa Spinal Muscular Atrophy Medicine Revenue by Country (2018-2023) & (US$ Million) Table 49. Middle East & Africa Spinal Muscular Atrophy Medicine Revenue by Country (2024-2029) & (US$ Million) Table 50. Global Spinal Muscular Atrophy Medicine Sales (K Pcs) by Type (2018-2023) Table 51. Global Spinal Muscular Atrophy Medicine Sales (K Pcs) by Type (2024-2029) Table 52. Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2018-2023) Table 53. Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2024-2029) Table 54. Global Spinal Muscular Atrophy Medicine Revenue (US$ Million) by Type (2018-2023) Table 55. Global Spinal Muscular Atrophy Medicine Revenue (US$ Million) by Type (2024-2029) Table 56. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2018-2023) Table 57. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2024-2029) Table 58. Global Spinal Muscular Atrophy Medicine Price (USD/Pcs) by Type (2018-2023) Table 59. Global Spinal Muscular Atrophy Medicine Price (USD/Pcs) by Type (2024-2029) Table 60. Global Spinal Muscular Atrophy Medicine Sales (K Pcs) by Application (2018-2023) Table 61. Global Spinal Muscular Atrophy Medicine Sales (K Pcs) by Application (2024-2029) Table 62. Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2018-2023) Table 63. Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2024-2029) Table 64. Global Spinal Muscular Atrophy Medicine Revenue (US$ Million) by Application (2018-2023) Table 65. Global Spinal Muscular Atrophy Medicine Revenue (US$ Million) by Application (2024-2029) Table 66. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2018-2023) Table 67. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2024-2029) Table 68. Global Spinal Muscular Atrophy Medicine Price (USD/Pcs) by Application (2018-2023) Table 69. Global Spinal Muscular Atrophy Medicine Price (USD/Pcs) by Application (2024-2029) Table 70. Astellas Pharma Inc. Corporation Information Table 71. Astellas Pharma Inc. Description and Business Overview Table 72. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 73. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Table 74. Astellas Pharma Inc. Recent Developments/Updates Table 75. AveXis, Inc. Corporation Information Table 76. AveXis, Inc. Description and Business Overview Table 77. AveXis, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 78. AveXis, Inc. Spinal Muscular Atrophy Medicine Product Table 79. AveXis, Inc. Recent Developments/Updates Table 80. Bioblast Pharma Ltd. Corporation Information Table 81. Bioblast Pharma Ltd. Description and Business Overview Table 82. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 83. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Table 84. Bioblast Pharma Ltd. Recent Developments/Updates Table 85. Cytokinetics, Inc. 24 Corporation Information Table 86. Cytokinetics, Inc. 24 Description and Business Overview Table 87. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 88. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Table 89. Cytokinetics, Inc. 24 Recent Developments/Updates Table 90. F. Hoffmann-La Roche Ltd. Corporation Information Table 91. F. Hoffmann-La Roche Ltd. Description and Business Overview Table 92. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 93. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Table 94. F. Hoffmann-La Roche Ltd. Recent Developments/Updates Table 95. Genethon Corporation Information Table 96. Genethon Description and Business Overview Table 97. Genethon Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 98. Genethon Spinal Muscular Atrophy Medicine Product Table 99. Genethon Recent Developments/Updates Table 100. Genzyme Corporation Corporation Information Table 101. Genzyme Corporation Description and Business Overview Table 102. Genzyme Corporation Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 103. Genzyme Corporation Spinal Muscular Atrophy Medicine Product Table 104. Genzyme Corporation Recent Developments/Updates Table 105. GMP-Orphan SAS Corporation Information Table 106. GMP-Orphan SAS Description and Business Overview Table 107. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 108. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Table 109. GMP-Orphan SAS Recent Developments/Updates Table 110. Ionis Pharmaceuticals, Inc. Corporation Information Table 111. Ionis Pharmaceuticals, Inc. Description and Business Overview Table 112. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 113. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Table 114. Ionis Pharmaceuticals, Inc. Recent Developments/Updates Table 115. Longevity Biotech, Inc Corporation Information Table 116. Longevity Biotech, Inc Description and Business Overview Table 117. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 118. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Table 119. Longevity Biotech, Inc Recent Developments/Updates Table 120. Neurodyn Inc. Corporation Information Table 121. Neurodyn Inc. Description and Business Overview Table 122. Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 123. Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Table 124. Neurodyn Inc. Recent Developments/Updates Table 125. Neurotune AG Corporation Information Table 126. Neurotune AG Description and Business Overview Table 127. Neurotune AG Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 128. Neurotune AG Spinal Muscular Atrophy Medicine Product Table 129. Neurotune AG Recent Developments/Updates Table 130. Novartis AG Corporation Information Table 131. Novartis AG Description and Business Overview Table 132. Novartis AG Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 133. Novartis AG Spinal Muscular Atrophy Medicine Product Table 134. Novartis AG Recent Developments/Updates Table 135. Sarepta Therapeutics, Inc. Corporation Information Table 136. Sarepta Therapeutics, Inc. Description and Business Overview Table 137. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 138. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Table 139. Sarepta Therapeutics, Inc. Recent Developments/Updates Table 140. Voyager Therapeutics, Inc. Corporation Information Table 141. Voyager Therapeutics, Inc. Description and Business Overview Table 142. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 143. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Table 144. Voyager Therapeutics, Inc. Recent Developments/Updates Table 145. Vybion, Inc. Corporation Information Table 146. Vybion, Inc. Description and Business Overview Table 147. Vybion, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 148. Vybion, Inc. Spinal Muscular Atrophy Medicine Product Table 149. Vybion, Inc. Recent Developments/Updates Table 150. WAVE Life Sciences Ltd. Corporation Information Table 151. WAVE Life Sciences Ltd. Description and Business Overview Table 152. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 153. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Table 154. WAVE Life Sciences Ltd. Recent Developments/Updates Table 155. Key Raw Materials Lists Table 156. Raw Materials Key Suppliers Lists Table 157. Spinal Muscular Atrophy Medicine Distributors List Table 158. Spinal Muscular Atrophy Medicine Customers List Table 159. Spinal Muscular Atrophy Medicine Market Trends Table 160. Spinal Muscular Atrophy Medicine Market Drivers Table 161. Spinal Muscular Atrophy Medicine Market Challenges Table 162. Spinal Muscular Atrophy Medicine Market Restraints Table 163. Research Programs/Design for This Report Table 164. Key Data Information from Secondary Sources Table 165. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of Spinal Muscular Atrophy Medicine Figure 2. Global Spinal Muscular Atrophy Medicine Market Value Comparison by Type (2023-2029) & (US$ Million) Figure 3. Global Spinal Muscular Atrophy Medicine Market Share by Type in 2022 & 2029 Figure 4. LMI-070 Product Picture Figure 5. ND-602 Product Picture Figure 6. NT-1654 Product Picture Figure 7. Nusinersen Product Picture Figure 8. NXD-30001 Product Picture Figure 9. Others Product Picture Figure 10. Global Spinal Muscular Atrophy Medicine Market Value Comparison by Application (2023-2029) & (US$ Million) Figure 11. Global Spinal Muscular Atrophy Medicine Market Share by Application in 2022 & 2029 Figure 12. Hospital Figure 13. Clinic Figure 14. Others Figure 15. Global Spinal Muscular Atrophy Medicine Revenue, (US$ Million), 2018 VS 2022 VS 2029 Figure 16. Global Spinal Muscular Atrophy Medicine Market Size (2018-2029) & (US$ Million) Figure 17. Global Spinal Muscular Atrophy Medicine Sales (2018-2029) & (K Pcs) Figure 18. Global Spinal Muscular Atrophy Medicine Average Price (USD/Pcs) & (2018-2029) Figure 19. Spinal Muscular Atrophy Medicine Report Years Considered Figure 20. Spinal Muscular Atrophy Medicine Sales Share by Manufacturers in 2022 Figure 21. Global Spinal Muscular Atrophy Medicine Revenue Share by Manufacturers in 2022 Figure 22. The Global 5 and 10 Largest Spinal Muscular Atrophy Medicine Players: Market Share by Revenue in 2022 Figure 23. Spinal Muscular Atrophy Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022 Figure 24. Global Spinal Muscular Atrophy Medicine Market Size by Region (US$ Million): 2018 VS 2022 VS 2029 Figure 25. North America Spinal Muscular Atrophy Medicine Sales Market Share by Country (2018-2029) Figure 26. North America Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2018-2029) Figure 27. U.S. Spinal Muscular Atrophy Medicine Revenue Growth Rate (2018-2029) & (US$ Million) Figure 28. Canada Spinal Muscular Atrophy Medicine Revenue Growth Rate (2018-2029) & (US$ Million) Figure 29. Europe Spinal Muscular Atrophy Medicine Sales Market Share by Country (2018-2029) Figure 30. Europe Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2018-2029) Figure 31. Germany Spinal Muscular Atrophy Medicine Revenue Growth Rate (2018-2029) & (US$ Million) Figure 32. France Spinal Muscular Atrophy Medicine Revenue Growth Rate (2018-2029) & (US$ Million) Figure 33. U.K. Spinal Muscular Atrophy Medicine Revenue Growth Rate (2018-2029) & (US$ Million) Figure 34. Italy Spinal Muscular Atrophy Medicine Revenue Growth Rate (2018-2029) & (US$ Million) Figure 35. Russia Spinal Muscular Atrophy Medicine Revenue Growth Rate (2018-2029) & (US$ Million) Figure 36. Asia Pacific Spinal Muscular Atrophy Medicine Sales Market Share by Region (2018-2029) Figure 37. Asia Pacific Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2018-2029) Figure 38. China Spinal Muscular Atrophy Medicine Revenue Growth Rate (2018-2029) & (US$ Million) Figure 39. Japan Spinal Muscular Atrophy Medicine Revenue Growth Rate (2018-2029) & (US$ Million) Figure 40. South Korea Spinal Muscular Atrophy Medicine Revenue Growth Rate (2018-2029) & (US$ Million) Figure 41. India Spinal Muscular Atrophy Medicine Revenue Growth Rate (2018-2029) & (US$ Million) Figure 42. Australia Spinal Muscular Atrophy Medicine Revenue Growth Rate (2018-2029) & (US$ Million) Figure 43. Taiwan Spinal Muscular Atrophy Medicine Revenue Growth Rate (2018-2029) & (US$ Million) Figure 44. Indonesia Spinal Muscular Atrophy Medicine Revenue Growth Rate (2018-2029) & (US$ Million) Figure 45. Thailand Spinal Muscular Atrophy Medicine Revenue Growth Rate (2018-2029) & (US$ Million) Figure 46. Malaysia Spinal Muscular Atrophy Medicine Revenue Growth Rate (2018-2029) & (US$ Million) Figure 47. Philippines Spinal Muscular Atrophy Medicine Revenue Growth Rate (2018-2029) & (US$ Million) Figure 48. Latin America Spinal Muscular Atrophy Medicine Sales Market Share by Country (2018-2029) Figure 49. Latin America Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2018-2029) Figure 50. Mexico Spinal Muscular Atrophy Medicine Revenue Growth Rate (2018-2029) & (US$ Million) Figure 51. Brazil Spinal Muscular Atrophy Medicine Revenue Growth Rate (2018-2029) & (US$ Million) Figure 52. Argentina Spinal Muscular Atrophy Medicine Revenue Growth Rate (2018-2029) & (US$ Million) Figure 53. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Market Share by Country (2018-2029) Figure 54. Middle East & Africa Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2018-2029) Figure 55. Turkey Spinal Muscular Atrophy Medicine Revenue Growth Rate (2018-2029) & (US$ Million) Figure 56. Saudi Arabia Spinal Muscular Atrophy Medicine Revenue Growth Rate (2018-2029) & (US$ Million) Figure 57. U.A.E Spinal Muscular Atrophy Medicine Revenue Growth Rate (2018-2029) & (US$ Million) Figure 58. Global Sales Market Share of Spinal Muscular Atrophy Medicine by Type (2018-2029) Figure 59. Global Revenue Market Share of Spinal Muscular Atrophy Medicine by Type (2018-2029) Figure 60. Global Spinal Muscular Atrophy Medicine Price (USD/Pcs) by Type (2018-2029) Figure 61. Global Sales Market Share of Spinal Muscular Atrophy Medicine by Application (2018-2029) Figure 62. Global Revenue Market Share of Spinal Muscular Atrophy Medicine by Application (2018-2029) Figure 63. Global Spinal Muscular Atrophy Medicine Price (USD/Pcs) by Application (2018-2029) Figure 64. Spinal Muscular Atrophy Medicine Value Chain Figure 65. Spinal Muscular Atrophy Medicine Production Process Figure 66. Channels of Distribution (Direct Vs Distribution) Figure 67. Distributors Profiles Figure 68. Bottom-up and Top-down Approaches for This Report Figure 69. Data Triangulation Figure 70. Key Executives Interviewed

Astellas Pharma Inc. AveXis, Inc. Bioblast Pharma Ltd. Cytokinetics, Inc. 24 F. Hoffmann-La Roche Ltd. Genethon Genzyme Corporation GMP-Orphan SAS Ionis Pharmaceuticals, Inc. Longevity Biotech, Inc Neurodyn Inc. Neurotune AG Novartis AG Sarepta Therapeutics, Inc. Voyager Therapeutics, Inc. Vybion, Inc. WAVE Life Sciences Ltd.